Innovation Pharmaceuticals Inc (IPIX)

[Yooper61]

If P beats Otezla, have you ever considered the cost of the 505(b)2 pathway and the increase in value (upfront and royalty) from a head to head smack down of Otezla at 12 weeks. We don’t need a partner for this. One more trial, twice the size of 2b. Phase 3 completed royalty on a head to head vs. phase 2 royalty on a comparative trial.